PMID- 28217523
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 2230-8210 (Print)
IS  - 2230-9500 (Electronic)
IS  - 2230-9500 (Linking)
VI  - 21
IP  - 1
DP  - 2017 Jan-Feb
TI  - Safe and pragmatic use of sodium-glucose co-transporter 2 inhibitors in type 2 
      diabetes mellitus: South Asian Federation of Endocrine Societies consensus 
      statement.
PG  - 210-230
LID - 10.4103/2230-8210.196029 [doi]
AB  - Diabetes prevalence shows a continuous increasing trend in South Asia. Although 
      well-established treatment modalities exist for type 2 diabetes mellitus (T2DM) 
      management, they are limited by their side effect profile. Sodium-glucose 
      co-transporter 2 inhibitors (SGLT2i) with their novel insulin-independent renal 
      action provide improved glycemic control, supplemented by reduction in weight and 
      blood pressure, and cardiovascular safety. Based on the clinical outcomes with 
      SGLT2i in patients with T2DM, treatment strategies that make a "good clinical 
      sense" are desirable. Considering the peculiar lifestyle, body types, dietary 
      patterns (long duration religious fasts), and the hot climate of the South Asian 
      population, a unanimous decision was taken to design specific, customized 
      guidelines for T2DM treatment strategies in these regions. The panel met for a 
      discussion three times so as to get a consensus for the guidelines, and only 
      unanimous consensus was included. After careful consideration of the quality and 
      strength of the available evidence, the executive summary of this consensus 
      statement was developed based on the American Association of Clinical 
      Endocrinologists/American College of Endocrinology protocol.
FAU - Kalra, Sanjay
AU  - Kalra S
AD  - Department of Endocrinology, Bharti Hospital, Karnal, Haryana, India.
FAU - Ghosh, Sujoy
AU  - Ghosh S
AD  - Institute of Post Graduate Medical Education and Research, Kolkata, West Bengal, 
      India.
FAU - Aamir, A H
AU  - Aamir AH
AD  - Department of Endocrinology and Metabolic Diseases, Post Graduate Medical 
      Institute, Hayatabad Medical Complex, Peshawar, Pakistan.
FAU - Ahmed, Md Tofail
AU  - Ahmed MT
AD  - Department of Endocrinology, BIRDEM and Ibrahim Medical College, Dhaka, 
      Bangladesh.
FAU - Amin, Mohammod Feroz
AU  - Amin MF
AD  - Department of Endocrinology, BIRDEM and Ibrahim Medical College, Dhaka, 
      Bangladesh.
FAU - Bajaj, Sarita
AU  - Bajaj S
AD  - Department of Medicine, MLN Medical College, Allahabad, Uttar Pradesh, India.
FAU - Baruah, Manash P
AU  - Baruah MP
AD  - Department of Endocrinology, Excel Centre Hospitals, Guwahati, Assam, India.
FAU - Bulugahapitiya, Uditha
AU  - Bulugahapitiya U
AD  - Department of Endocrinology, Colombo South Teaching Hospital, Colombo, Sri Lanka.
FAU - Das, A K
AU  - Das AK
AD  - Department of Medicine, Pondicherry Institute of Medical Sciences, Puducherry, 
      India.
FAU - Giri, Mimi
AU  - Giri M
AD  - BP Koirala Institute of Health Sciences, Dharan, Nepal.
FAU - Gunatilake, Sonali
AU  - Gunatilake S
AD  - Department of Endocrinology, Colombo South Teaching Hospital, Colombo, Sri Lanka.
FAU - Mahar, Saeed A
AU  - Mahar SA
AD  - Department of Medicine, National Institute of Cardiovascular Diseases, Karachi, 
      Pakistan.
FAU - Pathan, Md Faruque
AU  - Pathan MF
AD  - Department of Endocrinology, BIRDEM and Ibrahim Medical College, Dhaka, 
      Bangladesh.
FAU - Qureshi, Nazmul Kabir
AU  - Qureshi NK
AD  - Department of Endocrinology, Asgar Ali Hospital, Dhaka, Bangladesh.
FAU - Raza, S Abbas
AU  - Raza SA
AD  - Department of Medicine, Shaukat Khanum Memorial Cancer Hospital and Research 
      Centre, Lahore, Pakistan.
FAU - Sahay, Rakesh
AU  - Sahay R
AD  - Department of Endocrinology, Osmania Medical College, Hyderabad, Telangana, 
      India.
FAU - Shakya, Santosh
AU  - Shakya S
AD  - Diabetes, Thyroid and Endocrinology Care Centre, Kopundole, Nepal.
FAU - Shreshta, Dina
AU  - Shreshta D
AD  - Department of Endocrinology, Norvic Hospital, Kathmandu, Nepal.
FAU - Somasundaram, Noel
AU  - Somasundaram N
AD  - Department of Endocrinology, National Hospital of Sri Lanka, Colombo, Sri Lanka.
FAU - Sumanatilleke, Manilka
AU  - Sumanatilleke M
AD  - Department of Endocrinology, Teaching Hospital Karapitiya, Galle, Sri Lanka.
FAU - Unnikrishnan, A G
AU  - Unnikrishnan AG
AD  - Department of Endocrinology, Chellaram Institute of Diabetes, Pune, Maharashtra, 
      India.
FAU - Wijesinghe, Achini Madushani
AU  - Wijesinghe AM
AD  - Department of Endocrinology, National Hospital of Sri Lanka, Colombo, Sri Lanka.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - India
TA  - Indian J Endocrinol Metab
JT  - Indian journal of endocrinology and metabolism
JID - 101555690
PMC - PMC5240067
OTO - NOTNLM
OT  - Canagliflozin
OT  - South Asia
OT  - dapagliflozin
OT  - diabetes mellitus
OT  - empagliflozin
OT  - glycosuria
OT  - hyperglycemia
OT  - sodium-glucose co-transporter 2
COIS- There are no conflicts of interest.
EDAT- 2017/02/22 06:00
MHDA- 2017/02/22 06:01
PMCR- 2017/01/01
CRDT- 2017/02/21 06:00
PHST- 2017/02/21 06:00 [entrez]
PHST- 2017/02/22 06:00 [pubmed]
PHST- 2017/02/22 06:01 [medline]
PHST- 2017/01/01 00:00 [pmc-release]
AID - IJEM-21-210 [pii]
AID - 10.4103/2230-8210.196029 [doi]
PST - ppublish
SO  - Indian J Endocrinol Metab. 2017 Jan-Feb;21(1):210-230. doi: 
      10.4103/2230-8210.196029.